Therachon, which had raised $100m from investors including Pfizer Ventures and Novo, has agreed to be acquired by Pfizer in a deal that could potentially reach $810m.

Pfizer will pay $340m upfront and up to an additional $470m in milestone payments to purchase its portfolio company Therachon, providing an exit to Inserm Transfert Initiative.

Bennett, Coleman & Co has exited online pharmacy Myra and will receive shares in its new owner, Medlife, as part of the acquisition deal.

Evergy is set to exit utilities management software provider EnergySavvy in an acquisition by Tendril, following some $27m of funding.

OpenTable will offer Venga's customer analytics software to its restaurant clients following the acquisition, which will allow Think Food Group to exit.

Tencent will have to wait a little longer to exit livestreaming platform Douyu, which has decided to delay its initial public offering due to American tariffs on Chinese goods.

Center Laboratories Group and Formosa Laboratories are in line for exits as cancer drug developer Tot Biopharm aims to go public.

Regenerative implant producer OssDsign, based on research at Karolinska University Hospital and Uppsala University, hopes to list on the Nasdaq First North and raise $15.8m.

OpenTable will offer Venga's customer analytics software to its restaurant clients following the acquisition, which will allow Big Red Ventures to exit.

Meat substitute developer Beyond Meat, which has received backing from two corporate venturers, went public.